Share-based Payment Arrangement, Expense of Evelo Biosciences, Inc. from 31 Dec 2016 to 30 Sep 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Evelo Biosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2016 to 30 Sep 2023.
  • Evelo Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2023 was $2,476,000, a 29% decline year-over-year.
  • Evelo Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2023 was $11,171,000, a 31% decline year-over-year.
  • Evelo Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $15,158,000, a 4.3% decline from 2021.
  • Evelo Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $15,846,000, a 87% increase from 2020.
  • Evelo Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $8,468,000, a 3.7% increase from 2019.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Evelo Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2023 $11,171,000 $2,476,000 -$987,000 -29% 01 Jul 2023 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $12,158,000 $2,365,000 -$1,634,000 -41% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $13,792,000 $2,909,000 -$1,366,000 -32% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $15,158,000 $3,421,000 -$948,000 -22% 01 Oct 2022 31 Dec 2022 10-K 16 Mar 2023 2022 FY
Q3 2022 $16,106,000 $3,463,000 -$978,000 -22% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $17,084,000 $3,999,000 +$227,000 +6% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $16,857,000 $4,275,000 +$1,011,000 +31% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $15,846,000 $4,369,000 +$1,994,000 +84% 01 Oct 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $13,852,000 $4,441,000 +$2,396,000 +117% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $11,456,000 $3,772,000 +$1,679,000 +80% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $9,777,000 $3,264,000 +$1,309,000 +67% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $8,468,000 $2,375,000 +$360,000 +18% 01 Oct 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
Q3 2020 $8,108,000 $2,045,000 -$17,000 -0.82% 01 Jul 2020 30 Sep 2020 10-Q/A 29 Oct 2021 2021 Q3
Q2 2020 $8,125,000 $2,093,000 -$42,000 -2% 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021 2021 Q2
Q1 2020 $8,167,000 $1,955,000 +$2,000 +0.1% 01 Jan 2020 31 Mar 2020 10-Q 29 Apr 2021 2021 Q1
Q4 2019 $8,165,000 $2,015,000 +$450,000 +29% 01 Oct 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
Q3 2019 $7,715,000 $2,062,000 +$467,000 +29% 01 Jul 2019 30 Sep 2019 10-Q 30 Oct 2020 2020 Q3
Q2 2019 $7,248,000 $2,135,000 -$112,000 -5% 01 Apr 2019 30 Jun 2019 10-Q 31 Jul 2020 2020 Q2
Q1 2019 $7,360,000 $1,953,000 +$1,301,000 +200% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $6,059,000 $1,565,000 +$929,000 +146% 01 Oct 2018 31 Dec 2018 10-K 14 Feb 2020 2019 FY
Q3 2018 $5,130,000 $1,595,000 +$1,160,000 +267% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $3,970,000 $2,247,000 +$1,979,000 +738% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $1,991,000 $652,000 +$449,000 +221% 01 Jan 2018 31 Mar 2018 10-Q 03 May 2019 2019 Q1
Q4 2017 $1,542,000 $636,000 01 Oct 2017 31 Dec 2017 10-K 14 Feb 2020 2019 FY
Q3 2017 $435,000 01 Jul 2017 30 Sep 2017 10-Q 02 Nov 2018 2018 Q3
Q2 2017 $268,000 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018 2018 Q2
Q1 2017 $203,000 01 Jan 2017 31 Mar 2017 10-Q 31 May 2018 2018 Q1

Evelo Biosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $15,158,000 -$688,000 -4.3% 01 Jan 2022 31 Dec 2022 10-K 16 Mar 2023 2022 FY
2021 $15,846,000 +$7,378,000 +87% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $8,468,000 +$303,000 +3.7% 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
2019 $8,165,000 +$2,106,000 +35% 01 Jan 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
2018 $6,059,000 +$4,517,000 +293% 01 Jan 2018 31 Dec 2018 10-K 14 Feb 2020 2019 FY
2017 $1,542,000 +$1,123,000 +268% 01 Jan 2017 31 Dec 2017 10-K 14 Feb 2020 2019 FY
2016 $419,000 01 Jan 2016 31 Dec 2016 10-K 15 Feb 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.